Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 1.00 |
| ▸ | IRAK2 | O43187 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 1/20 | 1.00 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 1.00 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21106082 | 1.00 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23763239 | 1.00 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21105720 | 1.00 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23860570 | 1.00 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21070419 | 0.93 | IRAK4 (0.86) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL31664231 | 0.93 | IRAK4 (0.86) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21107419 | 0.93 | IRAK4 (0.86) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23945382 | 0.92 | IRAK4 (0.84) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23945438 | 0.92 | IRAK4 (0.84) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL22906395 | 0.92 | IRAK4 (0.84) | IRAK4IRAK2CLK1CLK2IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4132524-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | Aclaris Therapeutics, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |